Article info

Download PDFPDF
Concise report
Bcl-2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women
  1. Correspondence to J-M Anaya, Center for Autoimmune Diseases Research (CREA), School of Medicine, Rosario University; Carrera 24 # 63C-69, Bogotá, Colombia; anayajm{at}gmail.com
View Full Text

Citation

Delgado-Vega AM, Castiblanco J, Gómez LM, et al
Bcl-2 antagonist killer 1 (BAK1) polymorphisms influence the risk of developing autoimmune rheumatic diseases in women

Publication history

  • Accepted March 3, 2009
  • First published March 11, 2009.
Online issue publication 
January 26, 2010

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.